Aeglea Bio

AGLE NASDAQ
7.90
+0.11
+1.41%
盘后: 7.90 0 0.00% 17:00 08/16 EDT
开盘
7.83
昨收
7.79
最高
7.95
最低
7.73
成交量
4.12万
成交均量(3M)
16.57万
52周最高
11.16
52周最低
5.99
换手率
0.14%
市值
2.28亿
分时
5日
1月
3月
1年
5年

相关股票

微牛行情栏目提供Aeglea Bio AGLE股票价格,Aeglea Bio股票实时行情,公司简介,财报信息,股本结构等,掌握美港股行情走势,开盘价,收盘价,总市值,换手率,市盈率,收益率等数据,及时把握美股港股投资机会。

公司介绍

Aeglea BioTherapeutics, Inc. is a biotechnology company, which is engaged in the development of enzyme-based therapeutics in the field of amino acid metabolism to treat inborn errors of metabolism (IEM) and cancer. The Company's product pipeline includes AEB1102, AEB3103, AEB2109 and AEB4104. Its lead product candidate, AEB1102, is engineered to degrade the amino acid arginine and is being developed to treat over two extremes of arginine metabolism, including arginine excess in patients with Arginase I deficiency, an IEM, as well as some cancers, which have shown to have a metabolic dependence on arginine. AEB1102 reduces blood arginine levels in nonclinical and oncology clinical studies. AEB3103 targets the degradation of the amino acid cysteine/cystine. AEB2109 targets the degradation of the amino acid methionine. AEB4104 targets the reduction of elevated levels of the amino acid homocystine associated with the IEM classical homocystinuria.
展开 >

最近浏览

名称
价格
涨跌幅